Monoclonal antibody M-24 (Chiron/Fujirebio Europe NV)

N/A

Report date: 2023/01/14 14:15:26

Base Information

Drug NameMonoclonal antibody M-24 (Chiron/Fujirebio Europe NV)
Drug Alias NameM-24
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of organ transplantationGraft vs Host DiseaseArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFujirebio IncChiron Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChironFujirebio Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationGraft vs Host DiseaseArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A